S. Jung, S. Y. Kwon, J. Min, H. Bom, S. Ahn et al., 18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System, Eur J Nucl Med Mol Imaging, vol.46, pp.107-122, 2019.

D. Ripani, C. Caldarella, T. Za, D. A. Pizzuto, E. Rossi et al., Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective singlecenter evaluation, Eur J Nucl Med Mol Imaging, vol.46, pp.116-144, 2019.

S. F. Barrington, N. G. Mikhaeel, L. Kostakoglu, M. Meignan, M. Hutchings et al., Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group, J Clin Oncol, vol.32, pp.3048-58, 2014.

M. Cavo, E. Terpos, C. Nanni, P. Moreau, S. Lentzsch et al., Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group, Lancet Oncol, vol.18, pp.206-223, 2017.

C. Bailly, R. Leforestier, B. Jamet, T. Carlier, M. Bourgeois et al., PET imaging for initial staging and therapy assessment in multiple myeloma patients, Int J Mol Sci, vol.18, p.445, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01500327

T. B. Bartel, J. Haessler, T. Brown, J. D. Shaughnessy, F. Van-rhee et al., F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma, Blood, vol.114, pp.2068-76, 2009.

E. Zamagni, F. Patriarca, C. Nanni, B. Zannetti, E. Englaro et al., Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation, Blood, vol.118, pp.5989-95, 2011.

P. Moreau, M. Attal, D. Caillot, M. Macro, L. Karlin et al., Prospective evaluation of magnetic resonance imaging and [(18)F]fluorodeoxyglucose positron emission tomographycomputed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study, J Clin Oncol, vol.35, pp.2911-2919, 2017.

A. Stolzenburg, K. Lückerath, S. Samnick, M. Speer, K. Kneer et al., Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation, Eur J Nucl Med Mol Imaging, vol.45, pp.1694-704, 2018.

M. A. Aljama, M. H. Sidiqi, F. K. Buadi, M. Q. Lacy, M. A. Gertz et al., Utility and prognostic value of 18F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma, Am J Hematol, vol.93, pp.1518-1541, 2018.

L. Rasche, S. S. Chavan, O. W. Stephens, P. H. Patel, R. Tytarenko et al., Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing, Nat Commun, vol.8, p.268, 2017.

M. Weinstock and I. M. Ghobrial, Extramedullary multiple myeloma, Leuk Lymphoma, vol.54, pp.1135-1176, 2013.

C. Touzeau and P. Moreau, How I treat extramedullary myeloma, Blood, vol.127, pp.971-977, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01411096

S. Kumar, B. Paiva, K. C. Anderson, B. Durie, O. Landgren et al., International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, Lancet Oncol, vol.17, pp.328-374, 2016.

C. Nanni, E. Zamagni, M. Celli, P. Caroli, V. Ambrosini et al., The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients, Clin Nucl Med, vol.38, pp.74-83, 2013.

E. Zamagni, C. Nanni, K. Mancuso, P. Tacchetti, A. Pezzi et al., PET/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma, Clin Cancer Res, vol.21, pp.4384-90, 2015.

M. A. Dimopoulos, J. Hillengass, S. Usmani, E. Zamagni, S. Lentzsch et al., Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement, J Clin Oncol, vol.33, pp.657-64, 2015.

C. Nanni, E. Zamagni, A. Versari, S. Chauvie, A. Bianchi et al., Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian myeloma criteria for PET USe), Eur J Nucl Med Mol Imaging, vol.43, pp.414-435, 2016.

C. Nanni, A. Versari, S. Chauvie, E. Bertone, A. Bianchi et al., Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe), Eur J Nucl Med Mol Imaging, vol.45, pp.712-721, 2018.

T. Carlier and C. Bailly, State-of-the-art and recent advances in quantification for therapeutic follow-up in oncology using PET, Front Med (Lausanne), vol.2, p.18, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01817854

C. Bailly, T. Carlier, B. Jamet, E. T. Touzeau, C. Attal et al., Interim PET analysis in first-line therapy of multiple myeloma: prognostic value of ?SUVmax in the FDG-avid patients of the IMAJEM study, Clin Cancer Res, vol.24, pp.5219-5243, 2018.

W. A. Weber, S. I. Ziegler, R. Thödtmann, A. R. Hanauske, and M. Schwaiger, Reproducibility of metabolic measurements in malignant tumors using FDG PET, J Nucl Med, vol.40, pp.1771-1778, 1999.

C. Nanni, A. S. Cottereau, E. Lopci, C. Bodet-milin, M. Coronado et al., Report of the 6th International Workshop on PET in lymphoma, Leuk Lymphoma, vol.58, pp.2298-303, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01742975

E. Zamagni, C. Nanni, L. Dozza, T. Carlier, P. Tacchetti et al., Standardization of 18F-FDG PET/CT according to Deauville criteria for MRD evaluation in newly diagnosed transplant eligible multiple myeloma patients: joined analysis of two prospective randomized phase III trials, Blood, vol.132, p.257, 2018.